Skip to main content
Journal ArticleOPEN ACCESS

Otezla for plaque psoriasis and psoriatic arthritis

  • Chaplin S
  • Dunnill G
Prescriber (2015) 26(13-16) 33-35
DOI: 10.1002/psb.1375
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Apremilast (Otezla), a new oral PDE4 inhibitor, is licensed for the treatment of plaque psoriasis and psoriatic arthritis. Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Dr Giles Dunnill discusses its place in therapy.

Cite

CITATION STYLE

APA

Chaplin, S., & Dunnill, G. (2015). Otezla for plaque psoriasis and psoriatic arthritis. Prescriber, 26(13–16), 33–35. https://doi.org/10.1002/psb.1375

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free